Risk of Incident Immune-Mediated Inflammatory Diseases with Second Tumor Necrosis Factor Inhibitor Versus Alternative Biologic Therapy in Patients with Inflammatory Bowel Disease and First TNFi Exposure: A Real-World Cohort Study
In this large real-world IBD cohort with exposure to a TNFi, second TNFi use was associated with a higher risk of de-novo IMIDs compared to ustekinumab or vedolizumab.
Authors
- Aakash Desai (ORCID: https://orcid.org/0000-0002-6604-7712)
- Francis A. Farraye (ORCID: https://orcid.org/0000-0001-6371-2441)
- Himsikhar Khataniar (ORCID: https://orcid.org/0000-0001-7745-7277)
- Gursimran Kochhar (ORCID: https://orcid.org/0000-0002-0597-2760)
- Jana G. Hashash (ORCID: https://orcid.org/0000-0001-8305-9742)
Institutions
- Allegheny Health Network (US)
- Mayo Clinic in Florida (US)
- Drexel University (US)
Publication Details
- Journal
- Digestive Diseases and Sciences
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1007/s10620-025-09598-4
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82